查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1405902

反义和 RNAi 疗法市场规模、份额和趋势分析报告：按技术、按应用、按给药途径、按地区和细分市场预测，2024-2030 年

Antisense & RNAi Therapeutics Market Size, Share & Trends Analysis Report By Technology (RNA Interference, Antisense RNA), By Application (Ocular Disorder, Genetic Disorder), By Route of Administration, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 130 Pages | 商品交期: 2-10个工作天内

价格

反义和 RNAi 疗法市场成长和趋势：

Grand View Research, Inc.最新报告预测，到2030年，全球反义和RNAi治疗市场规模将达到146.6亿美元，2024年至2030年复合年增长率为18.12%。

增加对临床研究的资助，包括生物载体和奈米技术的开拓以及新药物分子的推出，对于产品开发至关重要，也是市场扩张的驱动力。

跨国医疗保健组织提高人们对各种疾病的认识并支持新治疗方法的开发。参与支持研究机构的临床试验的私人公司预计也将成为该领域扩张的主要推动力。例如，2022 年 3 月，Biogen Inc. 和 Ionis Pharmaceuticals, Inc. 宣布了一项临床实验反义寡核苷酸的 1 期试验结果，该试验用于治疗肌萎缩侧索硬化症 (ALS) 患者。随着基于反义和 RNAi 疗法的产品推出数量的增加，市场参与企业增加此类临床试验预计将推动市场成长。

反义和RNAi疗法会影响细胞的生长週期，可用于治疗多种针对核酸的疾病。 miRNA 再生基因表现和控制蛋白质生产的能力引起了人们的广泛关注，从而对工业进步产生了影响。根据美国科学促进会 2023 年 7 月发表的一篇论文，麻省大学陈医学院和 RUSH 大学医学中心开发的一种反义疗法可抑制X染色体脆折症候群患者细胞标本中一种名为FMRP 的蛋白质的产生.结果证明对恢復很有用。预计该行业的此类进步将在预测期内推动对用于治疗多种疾病的 RNAi 和反义核酸治疗药物的需求。

反义和 RNAi 治疗市场报告亮点

  • 反义RNA技术因其在神经退化性疾病和遗传性疾病等疾病的广泛应用，在2023年占据该技术领域最大的收益占有率。
  • RNA干扰领域预计将成为成长最快的技术领域。此技术又分为siRNA和miRNA。 miRNA 在维持细胞身份方面发挥关键作用，因此被用来更好地了解癌症扩散。
  • 从应用来看，遗传疾病领域占据主导地位，主要参与者越来越注重开发新型遗传疾病治疗方法。
  • 北美占据全球反义和RNAi治疗市场最大的销售份额。该地区的主导地位是由于该地区存在多个正在努力加强其行业地位的参与者。
  • 随着 Secarna 等主要企业在该地区营运和扩张，预计欧洲将在 2024 年至 2030 年的预测期内实现最快的成长。

目录

第一章调查方法与范围

第 2 章执行摘要

第 3 章反义和 RNAi 治疗市场变数、趋势和范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场抑制因素分析
  • 反义和 RNAi 治疗市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第四章反义和RNAi治疗药物市场：技术评估和趋势分析

  • 2023年及2030年技术市场占有率
  • 细分仪表板
  • 按技术展望分類的全球反义和 RNAi 治疗市场
  • 2018年至2030年市场规模、预测与趋势分析如下
    • RNA干扰
    • 反义RNA

第五章反义和RNAi治疗药物市场：应用估算和趋势分析

  • 2023年及2030年应用市场占有率
  • 细分仪表板
  • 全球反义和 RNAi 治疗市场按应用前景展望
  • 2018年至2030年市场规模、预测与趋势分析如下
    • 眼科
    • 心臟代谢和肾臟疾病
    • 呼吸系统疾病
    • 癌症
    • 神经退化性疾病
    • 遗传疾病
    • 感染疾病
    • 皮肤病
    • 其他的

第六章反义与RNAi治疗药物市场：给药途径估算与趋势分析

  • 2023 年及 2030 年给药途径市场占有率
  • 细分仪表板
  • 按给药途径分類的全球反义和 RNAi 疗法市场前景
  • 2018年至2030年市场规模、预测与趋势分析如下
    • 静脉注射
    • 鞘内注射
    • 皮下注射
    • 其他的

第七章反义和RNAi治疗药物市场：区域估计和趋势分析

  • 2023 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 全球区域市场概况
  • 2018-2030年市场规模及预测趋势分析：
  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 公司/竞争分类
  • 供应商形势
    • 主要经销商及通路伙伴名单
    • 主要客户
    • 2023 年主要企业股票分析
    • Olix Pharmaceuticals
    • GSK plc
    • Sanofi
    • Alnylam Pharmaceuticals, Inc.
    • Ionis Pharmaceuticals, Inc.
    • Benitec Biopharma Inc
    • Silence Therapeutics
    • Arbutus Biopharma
    • Bio-Path Holdings Inc
    • Antisense Therapeutics Limited.
Product Code: 978-1-68038-805-3

Antisense & RNAi Therapeutics Market Growth & Trends:

The global antisense & RNAi therapeutics market size is expected to reach USD 14.66 billion by 2030, registering a CAGR of 18.12% from 2024 to 2030, according to a new report by Grand View Research, Inc. Developments in biological vectors & nanotechnology and increased financial help for clinical investigations, including the launch of novel drug molecules, are critical in product development and are driving market expansion.

Multinational healthcare organizations raise awareness and assist in the development of novel remedies for a variety of ailments. Private institutes and companies participating in conducting trials through supporting research institutes are predicted to considerably fuel sector expansion. For instance, in March 2022, Biogen Inc. and Ionis Pharmaceuticals, Inc. announced outcomes from the Phase 1 study of an investigational antisense oligonucleotide for treating people with amyotrophic lateral sclerosis (ALS). Such increasing clinical trials through industry participants is anticipated to propel the market growth by rising the product launches based on antisense and RNAi therapies.

Antisense and RNAi therapies can be used to treat various disorders that impact the cell growth cycle and target nucleic acids. The ability of miRNA to regenerate gene expression and regulate protein production, consequently impacting industrial advancement, is receiving much attention. According to the article published by the American Association for the Advancement of Science in July 2023, an antisense therapy developed by UMass Chan Medical School and RUSH University Medical Center is found useful in restoring production of the protein FMRP in cell specimens taken from individuals suffering from fragile X syndrome. Such advancements in the industry are expected to propel the demand for RNAi and antisense therapeutics for treating numerous diseases over the forecast period.

Antisense & RNAi Therapeutics Market Report Highlights:

  • Antisense RNA technology accounted for the largest revenue share in 2023 in the technology segment due to its wide applications in diseases like neurodegenerative and genetic conditions.
  • The RNA interference segment is anticipated to witness the fastest growth in technology. This technology is further segmented into siRNA & miRNA. Due to miRNA's important role in sustaining cell identity, it's being employed to understand cancer spread better.
  • Based on application, the genetic disease segment's dominance can be attributed to key players' increasing focus on developing novel genetic disease treatments.
  • North America accounted for the largest revenue share in the global antisense and RNAi therapeutics market. The region's dominance can be attributed to the presence of several players in the region and their efforts to strengthen their position in the industry.
  • Europe is anticipated to register the fastest growth over the forecast period from 2024 to 2030, owing to key companies like Secarna operating and expanding in the region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Technology
    • 1.2.2. Route of Administration
    • 1.2.3. Application
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Technology outlook
    • 2.2.2. Route of Administration outlook
    • 2.2.3. Application outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Antisense & RNAi Therapeutics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Presence of strong pipeline product portfolio
      • 3.2.1.2. Introduction of technological advancements in drug delivery
      • 3.2.1.3. Implementation of favorable government initiatives & external funding for R&D exercises
      • 3.2.1.4. Rising collaborations between pharmaceutical companies
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Expensive and tedious research programs
      • 3.2.2.2. Delivery of RNAi therapeutics and off-target effects
  • 3.3. Antisense & RNAi Therapeutics Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Antisense & RNAi Therapeutics Market: Technology Estimates & Trend Analysis

  • 4.1. Technology Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. Global Antisense & RNAi Therapeutics Market by Technology Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. RNA Interference
      • 4.4.1.1. RNA Interference Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Antisense RNA
      • 4.4.2.1. Antisense RNA Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Antisense & RNAi Therapeutics Market: Application Estimates & Trend Analysis

  • 5.1. Application Market Share, 2023 & 2030
  • 5.2. Segment Dashboard
  • 5.3. Global Antisense & RNAi Therapeutics Market by Application Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 5.4.1. Ocular
      • 5.4.1.1. Ocular Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.2. Cardio metabolic & Renal Disorders
      • 5.4.2.1. Cardio metabolic & Renal Disorders Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.3. Respiratory Disorders
      • 5.4.3.1. Respiratory Disorders Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.4. Cancer
      • 5.4.4.1. Cancer Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.5. Neurodegenerative Disorders
      • 5.4.5.1. Neurodegenerative Disorders Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.6. Genetic Disorders
      • 5.4.6.1. Genetic Disorders Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.7. Infectious Diseases
      • 5.4.7.1. Infectious Diseases Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.8. Skin Diseases
      • 5.4.8.1. Skin Diseases Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 5.4.9. Others
      • 5.4.9.1. Others Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Antisense & RNAi Therapeutics Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Route of Administration Market Share, 2023 & 2030
  • 6.2. Segment Dashboard
  • 6.3. Global Antisense & RNAi Therapeutics Market, by Route of Administration Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 6.4.1. Intravenous Injections
      • 6.4.1.1. Intravenous Injections Market estimates and forecasts, 2018 to 2030 (USD million)
    • 6.4.2. Intrathecal Injections
      • 6.4.2.1. Intrathecal Injections Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.4.3. Subcutaneous Injections
      • 6.4.3.1. Subcutaneous Injections Market estimates and forecasts, 2018 to 2030 (USD Million)
    • 6.4.4. Others
      • 6.4.4.1. Others Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Antisense & RNAi Therapeutics Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2023 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Global Regional Market Snapshot
  • 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.5. North America
    • 7.5.1. U.S.
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Target disease prevalence
      • 7.5.1.3. Regulatory framework
      • 7.5.1.4. Competitive scenario
      • 7.5.1.5. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.5.2. Canada
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Target disease prevalence
      • 7.5.2.3. Regulatory framework
      • 7.5.2.4. Competitive scenario
      • 7.5.2.5. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6. Europe
    • 7.6.1. UK
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Target disease prevalence
      • 7.6.1.3. Regulatory framework
      • 7.6.1.4. Competitive scenario
      • 7.6.1.5. UK market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.2. Germany
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Target disease prevalence
      • 7.6.2.3. Regulatory framework
      • 7.6.2.4. Competitive scenario
      • 7.6.2.5. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.3. France
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Target disease prevalence
      • 7.6.3.3. Regulatory framework
      • 7.6.3.4. Competitive scenario
      • 7.6.3.5. France market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.4. Italy
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Target disease prevalence
      • 7.6.4.3. Regulatory framework
      • 7.6.4.4. Competitive scenario
      • 7.6.4.5. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.5. Spain
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Target disease prevalence
      • 7.6.5.3. Regulatory framework
      • 7.6.5.4. Competitive scenario
      • 7.6.5.5. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.6. Norway
      • 7.6.6.1. Key country dynamics
      • 7.6.6.2. Target disease prevalence
      • 7.6.6.3. Regulatory framework
      • 7.6.6.4. Competitive scenario
      • 7.6.6.5. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.7. Sweden
      • 7.6.7.1. Key country dynamics
      • 7.6.7.2. Target disease prevalence
      • 7.6.7.3. Regulatory framework
      • 7.6.7.4. Competitive scenario
      • 7.6.7.5. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.6.8. Denmark
      • 7.6.8.1. Key country dynamics
      • 7.6.8.2. Target disease prevalence
      • 7.6.8.3. Regulatory framework
      • 7.6.8.4. Competitive scenario
      • 7.6.8.5. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7. Asia Pacific
    • 7.7.1. Japan
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Target disease prevalence
      • 7.7.1.3. Regulatory framework
      • 7.7.1.4. Competitive scenario
      • 7.7.1.5. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.2. China
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Target disease prevalence
      • 7.7.2.3. Regulatory framework
      • 7.7.2.4. Competitive scenario
      • 7.7.2.5. China market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.3. India
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Target disease prevalence
      • 7.7.3.3. Regulatory framework
      • 7.7.3.4. Competitive scenario
      • 7.7.3.5. India market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.4. Australia
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Target disease prevalence
      • 7.7.4.3. Regulatory framework
      • 7.7.4.4. Competitive scenario
      • 7.7.4.5. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.5. South Korea
      • 7.7.5.1. Key country dynamics
      • 7.7.5.2. Target disease prevalence
      • 7.7.5.3. Regulatory framework
      • 7.7.5.4. Competitive scenario
      • 7.7.5.5. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.7.6. Thailand
      • 7.7.6.1. Key country dynamics
      • 7.7.6.2. Target disease prevalence
      • 7.7.6.3. Regulatory framework
      • 7.7.6.4. Competitive scenario
      • 7.7.6.5. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.8. Latin America
    • 7.8.1. Brazil
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Target disease prevalence
      • 7.8.1.3. Regulatory framework
      • 7.8.1.4. Competitive scenario
      • 7.8.1.5. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.8.2. Mexico
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Target disease prevalence
      • 7.8.2.3. Regulatory framework
      • 7.8.2.4. Competitive scenario
      • 7.8.2.5. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.8.3. Argentina
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Target disease prevalence
      • 7.8.3.3. Regulatory framework
      • 7.8.3.4. Competitive scenario
      • 7.8.3.5. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.9. MEA
    • 7.9.1. South Africa
      • 7.9.1.1. Key country dynamics
      • 7.9.1.2. Target disease prevalence
      • 7.9.1.3. Regulatory framework
      • 7.9.1.4. Competitive scenario
      • 7.9.1.5. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.9.2. Saudi Arabia
      • 7.9.2.1. Key country dynamics
      • 7.9.2.2. Target disease prevalence
      • 7.9.2.3. Regulatory framework
      • 7.9.2.4. Competitive scenario
      • 7.9.2.5. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.9.3. UAE
      • 7.9.3.1. Key country dynamics
      • 7.9.3.2. Target disease prevalence
      • 7.9.3.3. Regulatory framework
      • 7.9.3.4. Competitive scenario
      • 7.9.3.5. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
    • 7.9.4. Kuwait
      • 7.9.4.1. Key country dynamics
      • 7.9.4.2. Target disease prevalence
      • 7.9.4.3. Regulatory framework
      • 7.9.4.4. Competitive scenario
      • 7.9.4.5. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2023
    • 8.3.4. Olix Pharmaceuticals
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. GSK plc
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Sanofi
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Alnylam Pharmaceuticals, Inc.
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Ionis Pharmaceuticals, Inc.
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Benitec Biopharma Inc
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Silence Therapeutics
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Arbutus Biopharma
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Bio-Path Holdings Inc
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Antisense Therapeutics Limited.
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America antisense & RNAi therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 4 North America antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 5 North America antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 6 U.S. antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 7 U.S. antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 8 U.S. antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 9 Canada antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 10 Canada antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 11 Canada antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 12 Europe antisense & RNAi therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 13 Europe antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 14 Europe antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 15 Europe antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 16 Germany antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 17 Germany antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 18 Germany antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 19 UK antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 20 UK antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 21 UK antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 22 France antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 23 France antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 24 France antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 25 Italy antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 26 Italy antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 27 Italy antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 28 Spain antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 29 Spain antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 30 Spain antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 31 Denmark antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 32 Denmark antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 33 Denmark antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 34 Sweden antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 35 Sweden antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 36 Sweden antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 37 Norway antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 38 Norway antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 39 Norway antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific antisense & RNAi therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 44 China antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 45 China antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 46 China antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 47 Japan antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 48 Japan antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 49 Japan antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 50 India antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 51 India antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 52 India antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 53 South Korea antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 54 South Korea antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 55 South Korea antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 56 Australia antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 57 Australia antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 58 Australia antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 59 Thailand antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 60 Thailand antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 61 Thailand antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 62 Latin America antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 63 Latin America antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 64 Latin America surgical ablation market, by application, 2018 - 2030 (USD Million)
  • Table 65 Latin America laparoscopic ablation market, by application, 2018 - 2030 (USD Million)
  • Table 66 Latin America percutaneous ablation market, by application, 2018 - 2030 (USD Million)
  • Table 67 Latin America antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 68 Brazil antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 69 Brazil antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 70 Brazil surgical ablation market, by application, 2018 - 2030 (USD Million)
  • Table 71 Mexico antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 72 Mexico antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 73 Mexico surgical ablation market, by application, 2018 - 2030 (USD Million)
  • Table 74 Argentina antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 75 Argentina antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 76 Argentina surgical ablation market, by application, 2018 - 2030 (USD Million)
  • Table 77 MEA antisense & RNAi therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 78 MEA antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 79 MEA antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 80 MEA antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 81 South Africa antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 82 South Africa antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 83 South Africa antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 85 Saudi Arabia antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 86 Saudi Arabia antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 87 UAE antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 88 UAE antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 89 UAE antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)
  • Table 90 Kuwait antisense & RNAi therapeutics market, by technology, 2018 - 2030 (USD Million)
  • Table 91 Kuwait antisense & RNAi therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 92 Kuwait antisense & RNAi therapeutics market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in Asia Pacific
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in Middle East Africa
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Antisense & RNAi therapeutics market: market outlook
  • Fig. 14 Antisense & RNAi therapeutics competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Penetration and growth prospect mapping
  • Fig. 18 Industry value chain analysis
  • Fig. 19 Antisense & RNAi therapeutics market driver impact
  • Fig. 20 Antisense & RNAi therapeutics market restraint impact
  • Fig. 21 Antisense & RNAi therapeutics market strategic initiatives analysis
  • Fig. 22 Antisense & RNAi therapeutics market: Technology movement analysis
  • Fig. 23 Antisense & RNAi therapeutics market: Technology outlook and key takeaways
  • Fig. 24 RNA Interference market estimates and forecast, 2018 - 2030
  • Fig. 25 Antisense RNA estimates and forecast, 2018 - 2030
  • Fig. 26 Antisense & RNAi therapeutics Market: Route of administration movement analysis
  • Fig. 27 Antisense & RNAi therapeutics market: Route of administration outlook and key takeaways
  • Fig. 28 Intravenous injections market estimates and forecasts, 2018 - 2030
  • Fig. 29 Intrathecal injections market estimates and forecasts, 2018 - 2030
  • Fig. 30 Subcutaneous injections market estimates and forecasts, 2018 - 2030
  • Fig. 31 Other delivery methods market estimates and forecasts, 2018 - 2030
  • Fig. 32 Antisense & RNAi therapeutics market: application movement analysis
  • Fig. 33 Antisense & RNAi therapeutics market: application outlook and key takeaways
  • Fig. 34 Genetic disease market estimates and forecasts, 2018 - 2030
  • Fig. 35 Cancer market estimates and forecasts, 2018 - 2030
  • Fig. 36 Infectious disease market estimates and forecasts, 2018 - 2030
  • Fig. 37 Neurodegenerative disorders market estimates and forecasts, 2018 - 2030
  • Fig. 38 Cardiometabolic & renal disorders market estimates and forecasts, 2018 - 2030
  • Fig. 39 Ocular disorders market estimates and forecasts, 2018 - 2030
  • Fig. 40 Respiratory disorders market estimates and forecasts, 2018 - 2030
  • Fig. 41 Skin disorders market estimates and forecasts, 2018 - 2030
  • Fig. 42 Others market estimates and forecasts, 2018 - 2030
  • Fig. 43 Global antisense & RNAi therapeutics market: Regional movement analysis
  • Fig. 44 Global antisense & RNAi therapeutics market: Regional outlook and key takeaways
  • Fig. 45 Global antisense & RNAi therapeutics market share and leading players
  • Fig. 46 North America market share and leading players
  • Fig. 47 Europe market share and leading players
  • Fig. 48 Asia Pacific market share and leading players
  • Fig. 49 Latin America market share and leading players
  • Fig. 50 Middle East & Africa market share and leading players
  • Fig. 51 North America
  • Fig. 52 North America market estimates and forecasts, 2018 - 2030
  • Fig. 53 U.S.
  • Fig. 54 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 55 Canada
  • Fig. 56 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 57 Europe
  • Fig. 58 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 59 UK
  • Fig. 60 UK market estimates and forecasts, 2018 - 2030
  • Fig. 61 Germany
  • Fig. 62 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 63 France
  • Fig. 64 France market estimates and forecasts, 2018 - 2030
  • Fig. 65 Italy
  • Fig. 66 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 67 Spain
  • Fig. 68 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 69 Denmark
  • Fig. 70 Denmark market estimates and forecasts, 2018 - 2030
  • Fig. 71 Sweden
  • Fig. 72 Sweden market estimates and forecasts, 2018 - 2030
  • Fig. 73 Norway
  • Fig. 74 Norway market estimates and forecasts, 2018 - 2030
  • Fig. 75 Asia Pacific
  • Fig. 76 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 77 China
  • Fig. 78 China market estimates and forecasts, 2018 - 2030
  • Fig. 79 Japan
  • Fig. 80 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 81 India
  • Fig. 82 India market estimates and forecasts, 2018 - 2030
  • Fig. 83 Thailand
  • Fig. 84 Thailand market estimates and forecasts, 2018 - 2030
  • Fig. 85 South Korea
  • Fig. 86 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 87 Australia
  • Fig. 88 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 89 Latin America
  • Fig. 90 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 91 Brazil
  • Fig. 92 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 93 Mexico
  • Fig. 94 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 95 Argentina
  • Fig. 96 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 97 Middle East and Africa
  • Fig. 98 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 99 South Africa
  • Fig. 100 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 101 Saudi Arabia
  • Fig. 102 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 103 UAE
  • Fig. 104 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 105 Kuwait
  • Fig. 106 Kuwait market estimates and forecasts, 2018 - 2030
  • Fig. 107 Market share of key market players- Antisense & RNAi therapeutics market